ArticleClinical journal of gastroenterology2026
Long-term complete response of early gastric cancer to nivolumab: report of a case with disease-free survival for six years.
Article in Clinical journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although immune checkpoint inhibitors have demonstrated efficacy in advanced gastric cancer, reports of long-term complete remission in early-stage disease are lacking. We report a case of a 75-year-old man who presented with concurrent malignant melanoma and early gastric cancer (cT1bN0M0). Following surgical excision of melanoma with positive sentinel lymph node biopsy (T3bN1M0 Stage III), we prioritized treatment of advanced melanoma over early gastric cancer and initiated nivolumab adjuvant therapy every 2 weeks. After six cycles, treatment was discontinued due to drug-induced pneumonitis with elevated KL-6 levels. Repeat endoscopy performed 2 months after initial examination revealed partial tumor regression, with complete disappearance of the gastric lesion confirmed 4 months later. Histopathological examination showed no malignant findings. The patient achieved complete response of gastric cancer with only six cycles of nivolumab, despite negative PD-L1 expression (combined positive score 0%). During 6 years of follow-up, endoscopic and CT examinations consistently showed no gastric cancer recurrence, maintaining complete response. This case demonstrates sustained long-term efficacy of nivolumab against early gastric cancer, achieving 6-year disease-free survival with minimal treatment exposure. These findings suggest that immune checkpoint inhibitors may represent potential treatment options for patients with early gastric cancer contraindicated for surgery, even in PD-L1-negative cases.
Indexed as
Identifiers
41499033What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.